CliffBio
small molecule

ERYTHROMYCIN

ERYTHROMYCIN

Loss of exclusivity—loss of exclusivity
CompanyAlembic →See this company's full patent-cliff portfolio

Drug detail

Brand nameERYTHROMYCIN
Active ingredientERYTHROMYCIN
Strength250MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2023
Marketing statusRX

More from Alembic

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.